• If you are wondering whether Incyte's current share price still offers value or has already priced in recent enthusiasm, the next sections will walk through what the numbers actually say.
• Over the past year the stock has returned 55.0%, with shorter term moves of 2.4% over 7 days, 2.8% over 30 days and a year to date return of a 4.4% decline, which can change how the market views both its growth potential and its risks.
• Recent coverage has focused on Incyte's position in biotech and the progress of its drug portfolio. This helps explain why sentiment has been shifting. This context matters because news around key therapies, partnerships or pipeline developments often feeds directly into how investors think about what the business is worth.
• Even so, Simply Wall St's valuation checks give Incyte a value score of 2 out of 6. Next comes a closer look at how different valuation methods stack up for the stock, and how a broader framework at the end of the article can help you interpret those results more clearly.

Incyte scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Incyte Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today using a required rate of return. It is essentially asking what those future dollars are worth in current terms.

For Incyte, the 2 Stage Free Cash Flow to Equity model starts with last twelve month free cash flow of about $1.43b. Analysts have provided forecasts for several years ahead, and Simply Wall St then extends those projections further, with free cash flow for 2030 estimated at $575.95m and additional extrapolated values through 2035.

Pulling all of those projected cash flows together, the model arrives at an estimated intrinsic value of $49.73 per share. Compared to the current share price, the implied intrinsic discount figure of 94.9% indicates that the stock screens as significantly overvalued using this approach.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Incyte may be overvalued by 94.9%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Incyte Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it directly links what you pay for the stock to the earnings the business is currently generating. It gives you a quick sense of how many dollars investors are willing to pay today for each dollar of earnings.

What counts as a "normal" or "fair" P/E depends on how the market views a company’s growth prospects and risk profile. Higher expected growth or lower perceived risk tends to support a higher P/E, while slower growth or higher risk usually points to a lower multiple.

Incyte currently trades on a P/E of 13.52x. That sits below both the Biotechs industry average of 17.28x and the broader peer group average of 22.64x. Simply Wall St’s Fair Ratio for Incyte is 12.08x, which is a proprietary estimate of the P/E that might be expected given factors such as earnings growth characteristics, profit margins, industry, market cap and specific risks.

The Fair Ratio can be more useful than simple peer or industry comparisons because it adjusts for these company specific drivers instead of assuming all biotechs deserve the same multiple. With the current P/E of 13.52x sitting above the Fair Ratio of 12.08x, the stock screens as somewhat expensive on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Incyte Narrative

Earlier the article mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St give you a clear story for Incyte that ties together your view on Jakafi’s 2028 patent cliff, the longer dated pipeline and market risks into a concrete forecast for future revenue, earnings and margins. It then converts that forecast into a Fair Value you can compare with the current share price to help you assess whether the stock appears expensive or cheap. Multiple Narratives on the Community page already range from a bearish Fair Value of about US$72, built on 2.1% annual revenue growth, a 17.3% margin and a 20.4x future P/E, through to a bullish Fair Value of US$135 based on 18.4% annual revenue growth, a 25.4% margin and a 16.6x future P/E. There is also a consensus style view around US$80 that sits in between. All of these automatically update as new earnings, guidance or drug news comes through so you can keep your own Incyte story aligned with the latest information.

For Incyte however we will make it really easy for you with previews of two leading Incyte Narratives:

Fair Value: US$135.00

Implied discount or premium vs last close: about 28.2% premium to this Fair Value based on the current share price of US$96.91

Revenue growth assumption: 18.38% per year

• Leans on late stage oncology and dermatology drugs such as Opzelura, Niktimvo, tafasitamab and retifanlimab, plus international expansion, to broaden revenue beyond Jakafi.
• Assumes earnings rise to US$2.2b by around April 2029 with profit margins edging up to about 25.4%, supported by partnerships and a fuller pipeline.
• Requires the market to value those 2029 earnings at a 16.6x P/E, slightly higher than current biotech peers, to support a Fair Value of US$135.

Fair Value: US$72.33

Implied discount or premium vs last close: about 34.0% premium to this Fair Value based on the current share price of US$96.91

Revenue growth assumption: 2.08% per year

• Focuses on heavy dependence on Jakafi and the 2028 patent cliff, with concerns that newer products may not scale quickly enough to offset pressure from biosimilars and pricing regulation.
• Builds in slower revenue growth and a margin squeeze to about 17.3%, with earnings projected at roughly US$943.5m by around April 2029.
• Assumes the shares would still trade on a 20.4x P/E in 2029, which lifts the multiple even as growth and profitability are modelled as weaker, leading to a Fair Value of about US$72.

Both snapshots use the same current share price, but they rest on very different views of how quickly Incyte can reduce its reliance on Jakafi, how the pipeline performs, and what P/E multiple the market is willing to pay for that earnings profile.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Incyte on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Incyte? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.